News

DSM enters algae alliance
Enlarge image

BusinessFranceGermany

DSM enters algae alliance

12.10.2012 - Dutch Royal DSM collaborates with a Sanofi subsidiary to stretch ist algal expression system into animal health vaccine production.

This strategic alliance could change the established ways of vaccine production. DSM Nutritional Product, a subsidiary of Dutch Royal DSM N.V., has announced a Development and Option to License Agreement with animal health specialist Merial Limited, part of the US-subsidiary of French Sanofi S.A. The partners want to bring together their expertise to produce animal health vaccines in DSM’s proprietary algal expression system. Compared to existing techniques based on eggs or cell cultures, the new platform could present a faster and more efficient production method. Financial details were not disclosed. It is known, however, that Merial will provide R&D funding to value DSM’s research efforts. DSM would also be eligible to receive milestone payments, license fees and royalties on sales of a successfully launched product.

Almost two years ago Royal DSM acquired Martek Biosciences Corporation from Columbia (Maryland, USA) in a billion dollar deal. This marked DSM’s transformation into a life sciences and materials sciences company. In Columbia omega-3- and omega-6-products are produced by algae. Former Martek CEO Peter Nitze, now President of the Nutritional Lipids division of DSM Nutritional Products, welcomes the expansion of the algae-production portfolio: „We are pleased to join Merial on this important project that we expect will validate the algal expression system as a viable alternative to known vaccine production methods.“ DSM is better known as a global player in biofuel production. The company hit the news earlier this year when it announced the start of a joint venture with US-ethanol producer POET, LLC.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/dsm-wants-algae-made-vaccines.html

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • EPIGENOMICS3.78 EUR11.83%
  • MOLOGEN7.75 EUR6.02%

FLOP

  • SANTHERA92.70 CHF-7.39%
  • MEDIGENE4.40 EUR-2.87%
  • ADDEX3.82 CHF-2.80%

TOP

  • SANTHERA92.70 CHF54.8%
  • EPIGENOMICS3.78 EUR18.1%
  • BB BIOTECH143.70 EUR11.1%

FLOP

  • WILEX2.40 EUR-11.1%
  • BIOFRONTERA2.40 EUR-10.4%
  • VITA 343.77 EUR-9.4%

TOP

  • SANTHERA92.70 CHF3622.9%
  • CO.DON2.45 EUR206.3%
  • PAION2.38 EUR150.5%

FLOP

  • CYTOS0.26 CHF-93.4%
  • THERAMETRICS0.08 CHF-42.9%
  • MERCK KGAA66.43 EUR-42.3%

No liability assumed, Date: 02.09.2014